Siren L.L.C. Has $35.77 Million Position in enGene Holdings Inc. $ENGN

Siren L.L.C. raised its stake in enGene Holdings Inc. (NASDAQ:ENGN) by 57.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,253,159 shares of the company’s stock after purchasing an additional 1,916,895 shares during the period. Siren L.L.C. owned 0.08% of enGene worth $35,774,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Sei Investments Co. acquired a new stake in shares of enGene during the 1st quarter worth about $409,000. Monashee Investment Management LLC grew its stake in enGene by 8.5% in the 1st quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock valued at $2,179,000 after buying an additional 25,000 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in enGene in the 1st quarter valued at about $251,000. XTX Topco Ltd bought a new position in enGene in the 4th quarter valued at about $216,000. Finally, Vestal Point Capital LP lifted its position in enGene by 185.1% during the fourth quarter. Vestal Point Capital LP now owns 1,055,000 shares of the company’s stock worth $9,527,000 after acquiring an additional 685,000 shares during the last quarter. 64.16% of the stock is owned by institutional investors.

enGene Price Performance

NASDAQ:ENGN opened at $1.89 on Friday. enGene Holdings Inc. has a 52 week low of $1.40 and a 52 week high of $12.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.57 and a current ratio of 12.57. The firm’s 50-day simple moving average is $1.76 and its 200 day simple moving average is $5.87. The firm has a market cap of $126.61 million, a price-to-earnings ratio of -0.87 and a beta of -0.28.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Monday, June 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. During the same quarter in the prior year, the company posted $0.51 earnings per share. As a group, sell-side analysts predict that enGene Holdings Inc. will post -1.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Citizens Jmp cut enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th. UBS Group lowered their target price on enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. HC Wainwright dropped their price target on enGene from $6.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Citigroup downgraded enGene from a “market outperform” rating to a “market perform” rating in a research note on Friday, May 8th. Finally, Piper Sandler lowered enGene from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $7.00 to $4.00 in a report on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $11.05.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.